Evidence map›Paper›PMID 36178579›Full record

ArticleProbiotics and antimicrobial proteins2023

Immune-Enhancing Effect of Heat-Treated Levilactobacillus brevis KU15159 in RAW 264.7 Cells.

Chang-Hoon Hwang, Kee-Tae Kim, Na-Kyoung Lee, Hyun-Dong Paik

Open access · bronzeAbstract read
In one paragraph

Article in Probiotics and antimicrobial proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Microbiome-Modulating Effects of Heat-TreatedJournal of microbiology and biotechnology · 2026
    Trial
  2. Article
  3. Comparative Immunomodulatory Profiles ofJournal of microbiology and biotechnology · 2026
    Article
  4. Lactose-Free Fermented Milk Production UsingJournal of microbiology and biotechnology · 2026
    Article
  5. Effect ofPreventive nutrition and food science · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. ProbioticFrontiers in cellular and infection microbiology · 2024
    Article
  13. Article
  14. Paraprobiotic derived fromFrontiers in immunology · 2024
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chang-Hoon HwangDepartment of Food Science and Biotechnology of Animal Resources, Konkuk University, Seoul, 05029, Republic of Korea.
Kee-Tae KimResearch Center, WithBio Inc., Seoul, 05029, Republic of Korea.
Na-Kyoung LeeDepartment of Food Science and Biotechnology of Animal Resources, Konkuk University, Seoul, 05029, Republic of Korea.
Hyun-Dong PaikDepartment of Food Science and Biotechnology of Animal Resources, Konkuk University, Seoul, 05029, Republic of Korea. hdpaik@konkuk.ac.kr.
Konkuk University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics are alive microbes that present beneficial to the human's health. They influence immune responses through stimulating antibody production, activating T cells, and altering cytokine expression. The probiotic characteristics of Levilactobacillus brevis KU15159 were evaluated on the tolerance and adherence to gastrointestinal conditions. L. brevis KU15159 was safe in a view of producing various useful enzymes and antibiotic sensitivity. Heat-treated L. brevis KU15159 increased production of nitric oxide (NO) and phagocytic activity in RAW 264.7 cells. In addition, heat-treated L. brevis KU15159 upregulated the expression of inducible nitric oxide synthase (iNOS) and proinflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, at protein as well as mRNA levels. In addition, the mitogen-activated protein kinase (MAPK) pathway, which regulates the immune system, was activated by heat-treated L. brevis KU15159. Therefore, L. brevis KU15159 exhibited an immune-enhancing effect by the MAPK pathway in macrophage.

Indexed as

Levilactobacillus brevisAnimalsCytokinesHot TemperatureHumansLipopolysaccharidesMiceMitogen-Activated Protein KinasesNF-kappa BNitric OxideNitric Oxide Synthase Type IIRAW 264.7 CellsTumor Necrosis Factor-alphaCytokinesLipopolysaccharidesMitogen-Activated Protein KinasesNF-kappa BNitric OxideNitric Oxide Synthase Type IITumor Necrosis Factor-alphaImmune-enhancingLevilactobacillus brevisMAPK signaling pathwayProbioticsRAW 264.7 cell

Identifiers

PMID36178579
PMCPMC9523639
OpenAlexW4298089155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.